Drug Profile
Minocycline - Solvotrin Innovations
Latest Information Update: 16 Oct 2021
Price :
$50
*
At a glance
- Originator Solvotrin Innovations
- Class Amides; Anti-inflammatories; Antiacnes; Antibacterials; Dimethylamines; Eye disorder therapies; Neuroprotectants; Skin disorder therapies; Small molecules; Tetracyclines
- Mechanism of Action Matrix metalloproteinase 9 inhibitors; Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 24 Jun 2019 Discontinued - Phase-II for Cardiovascular disorders (In the elderly, In adults) in Ireland (PO)
- 10 Sep 2018 Chemical structure information added
- 10 Apr 2017 Solvotrin Innovation completes a phase II trials in Cardiovascular disorders (In adults, In the elderly) in Ireland (PO) (EudraCT2015-002387-16)